The study found that the influenza vaccine for the 2022-2023 season was moderately effective in reducing influenza-A-associated emergency and urgent care encounters and hospitalizations in the US. The research involved adults with acute respiratory illness and used data from the VISION Network. It found that overall vaccine effectiveness was 44.0% against influenza-A-associated emergency and urgent care encounters and 35.0% against hospitalizations. Similar effectiveness was observed among different at-risk groups. The study had limitations, including a lack of ability to compare vaccine effectiveness by age group and representation of all encounters among adults in the US by the included health care systems. The authors concluded that the vaccine showed moderate effectiveness across different care settings and at-risk groups.
Source link
2022-2023 Influenza Vaccine Moderately Effective Against Hospitalizations
